Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research
208
mi
from 43215
Kalamazoo, MI
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research
208
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Neurological Research Center
694
mi
from 43215
Hattiesburg, MS
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Neurological Research Center
694
mi
from 43215
Hattiesburg, MS
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
CRI Lifetree Marlton
428
mi
from 43215
Marlton, NJ
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
CRI Lifetree Marlton
428
mi
from 43215
Marlton, NJ
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Princeton Medical Institute
442
mi
from 43215
Princeton, NJ
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Princeton Medical Institute
442
mi
from 43215
Princeton, NJ
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Nathan Kline Institute
481
mi
from 43215
Orangeburg, NY
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Nathan Kline Institute
481
mi
from 43215
Orangeburg, NY
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
University of Rochester Medical Center; Monroe Community Hospital
354
mi
from 43215
Rochester, NY
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
University of Rochester Medical Center; Monroe Community Hospital
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Memory Center
348
mi
from 43215
Charlotte, NC
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Memory Center
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Raleigh Neurology Associates
371
mi
from 43215
Raleigh, NC
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Raleigh Neurology Associates
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center
2026
mi
from 43215
Portland, OR
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
The Clinical Trial Center, LLC
418
mi
from 43215
Jenkintown, PA
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
The Clinical Trial Center, LLC
418
mi
from 43215
Jenkintown, PA
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Northeastern Pennsylvania Memory
386
mi
from 43215
Plains, PA
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Northeastern Pennsylvania Memory
386
mi
from 43215
Plains, PA
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Rhode Island Mood & Memory Research Institute
621
mi
from 43215
East Providence, RI
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Rhode Island Mood & Memory Research Institute
621
mi
from 43215
East Providence, RI
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
619
mi
from 43215
Providence, RI
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Senior Adults Specialty Research
1065
mi
from 43215
Austin, TX
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Senior Adults Specialty Research
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
907
mi
from 43215
Dallas, TX
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
907
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Lifetree Clinical Research
1513
mi
from 43215
Salt Lake City, UT
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Lifetree Clinical Research
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Research Associates, Inc.
547
mi
from 43215
Bennington, VT
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Research Associates, Inc.
547
mi
from 43215
Bennington, VT
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Hospital Italiano
5385
mi
from 43215
Buenos Aires,
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Hospital Italiano
5385
mi
from 43215
Buenos Aires,
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Bioclinica Research
795
mi
from 43215
Orlando, FL
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Bioclinica Research
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver Anschutz Medical Campus
1154
mi
from 43215
Aurora, CO
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver Anschutz Medical Campus
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated:  12/31/1969
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated: 12/31/1969
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated:  12/31/1969
Howard University
328
mi
from 43215
Washington,
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated: 12/31/1969
Howard University
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Endothelial Facilitation in Alzheimer's Disease
Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  12/31/1969
UMass Medical School/ UMass Memorial Medical Center
607
mi
from 43215
Worcester, MA
Endothelial Facilitation in Alzheimer's Disease
Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 12/31/1969
UMass Medical School/ UMass Memorial Medical Center
607
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Health
1661
mi
from 43215
Phoenix, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Health
1661
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Health
1661
mi
from 43215
Phoenix, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Health
1661
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
1669
mi
from 43215
Sun City, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
1669
mi
from 43215
Sun City, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC Davis
2060
mi
from 43215
Davis, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC Davis
2060
mi
from 43215
Davis, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC, Irvine
1959
mi
from 43215
Irvine, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC, Irvine
1959
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Southern California
1970
mi
from 43215
Los Angeles, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Southern California
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC Irvine
1960
mi
from 43215
Orange, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC Irvine
1960
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
2105
mi
from 43215
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
2105
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
2105
mi
from 43215
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
2105
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
2105
mi
from 43215
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
2105
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco Memory Center
1982
mi
from 43215
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco Memory Center
1982
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mt Sinai Medical Center
991
mi
from 43215
Miami Beach, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mt Sinai Medical Center
991
mi
from 43215
Miami Beach, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Kansas
620
mi
from 43215
Kansas City, KA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Kansas
620
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University
306
mi
from 43215
Winston-Salem, NC
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Jefferson
414
mi
from 43215
Philadelphia, PA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Jefferson
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
619
mi
from 43215
Providence, RI
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
The University of Tennessee
280
mi
from 43215
Knoxville, TN
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
The University of Tennessee
280
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials